Clinical Trial Update: Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated copanlisib in combination with standard immunochemotherapy for relapsed indolent non-Hodgkin lymphoma. The study was terminated and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Non-hodgkin Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)

Snippet

Sponsor: Bayer | Conditions: Lymphoma, Non-Hodgkin | Phase 3 | Status: TERMINATED | Results posted: 2024-12-11